Cargando…
Remdesivir
Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/ https://www.ncbi.nlm.nih.gov/pubmed/37061276 http://dx.doi.org/10.1016/bs.podrm.2022.11.003 |
_version_ | 1784884777503948800 |
---|---|
author | Bakheit, Ahmed H. Darwish, Hany Darwish, Ibrahim A. Al-Ghusn, Ahmed I. |
author_facet | Bakheit, Ahmed H. Darwish, Hany Darwish, Ibrahim A. Al-Ghusn, Ahmed I. |
author_sort | Bakheit, Ahmed H. |
collection | PubMed |
description | Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations. |
format | Online Article Text |
id | pubmed-9910426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99104262023-02-10 Remdesivir Bakheit, Ahmed H. Darwish, Hany Darwish, Ibrahim A. Al-Ghusn, Ahmed I. Profiles Drug Subst Excip Relat Methodol Article Remdesivir, marketed under the brand name Veklury, is an antiviral drug with a broad spectrum of activity. There were various countries where the use of Remdesivir for the treatment of COVID-19 was authorized during the pandemic. Remdesivir was first designed to treat hepatitis C, but it was later tested for Ebola virus sickness and Marburg virus infections. Remdesivir is a prodrug designed to facilitate the intracellular transport of GS-441524 monophosphate and its subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase. The objective of this chapter is to provide a comprehensive review of Remdesivir (GS-5734), including its nomenclature, physiochemical properties, preparation methods, identification procedures, numerous qualitative and quantitative analytical techniques, ADME profiles, and pharmacological effects. In addition, the chapter provides a variety of chromatographic and spectroscopic techniques for separating brimonidine from other drugs in combination formulations. Elsevier Inc. 2023 2023-02-09 /pmc/articles/PMC9910426/ /pubmed/37061276 http://dx.doi.org/10.1016/bs.podrm.2022.11.003 Text en Copyright © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Bakheit, Ahmed H. Darwish, Hany Darwish, Ibrahim A. Al-Ghusn, Ahmed I. Remdesivir |
title | Remdesivir |
title_full | Remdesivir |
title_fullStr | Remdesivir |
title_full_unstemmed | Remdesivir |
title_short | Remdesivir |
title_sort | remdesivir |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910426/ https://www.ncbi.nlm.nih.gov/pubmed/37061276 http://dx.doi.org/10.1016/bs.podrm.2022.11.003 |
work_keys_str_mv | AT bakheitahmedh remdesivir AT darwishhany remdesivir AT darwishibrahima remdesivir AT alghusnahmedi remdesivir |